Clinical study in treatment of malignant ascites with intraperitoneal injection bevacizumab and 5-FU combined with intraperitoneal hyperthermic perfusion chemotherapy

Objective To study the efficacy and safety of intraperitoneal injection bevacizumab and 5-FU combined with intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites.Methods Fifty-seven cases of the patients with malignant ascites were randomly divided into group of intraperitoneal injection bevacizumab and 5-FU of malignant ascites(treatment group) and group of intraperitoneal injection only 5-FU(control group).Ascites of the patients from the two groups were both exhausted first.Sterilization 0.9% saline with 43 to 45 ℃ was injected into the peritoneal cavity of all patients,constantly and effectively circulated more than 40 minutes,then the saline was exhausted.The patients in treatment group were accepted intraperitoneal injection with bevacizumab(avastin) 300 mg and 5-FU 1 g.The same therapy applied to the control group except adding bevacizumab.Results Among the evaluable 57 cases,the total effective rate of the treatment group was 85.71%,while 58.62% of the control group.Two groups had significant difference(P0.05).All the patients were of good tolerance in whole therapy and no severe side effects happened.Conclusion The treatment of malignant ascites with intraperitoneal injection bevacizumab and 5-FU,combined with intraperitoneal hyperthermic perfusion chemotherapy is effective and secure.